# Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers

> **NCT03956134** · PHASE1 · COMPLETED · sponsor: **Grünenthal GmbH** · enrollment: 10 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Tapentadol Test Product 1
- **DRUG:** Tapentadol Test Product 2
- **DRUG:** Tapentadol Prolonged-release Reference Product

## Key facts

- **NCT ID:** NCT03956134
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03956134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03956134, "Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03956134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*